English
Back
Download
Log in to access Online Inquiry
Back to the Top

NEWS

Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib


Syndax Pharmaceuticals (SNDX)announced positive topline results from the AUGMENT-101 trial of revumenib in relapsed/refractory mNPM1 AML patients. The trial met its primary endpoint with a 23% complete remission rate (p-value = 0.0014) and achieved a 47% overall response rate in a heavily pre-treated population. The safety profile was favorable, with only 5% of patients discontinuing due to treatment-related adverse events. The company plans to submit a supplemental New Drug Application (sNDA) in the first half of 2025, following anticipated FDA approval for KMT2Ar acute leukemia in Q4 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
5445 Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    8982
    Followers
    54
    Following
    107K
    Visitors
    Follow